Annual report pursuant to Section 13 and 15(d)

Note 1 - Corporate Information (Details Textual)

v3.23.1
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
May 31, 2013
Cash, Cash Equivalents, and Short-Term Investments, Total $ 59,200    
Net Income (Loss) Attributable to Parent, Total (33,277) $ (45,738)  
Retained Earnings (Accumulated Deficit), Total $ (290,421) $ (257,144)  
Pieris Pharmaceuticals GmbH [Member]      
Business Acquisition, Percentage of Voting Interests Acquired     100.00%